Clinical Trial Update: A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating VX-702, an investigational p38 MAP kinase inhibitor, in patients with rheumatoid art…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• VX-702

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED